Abstract: The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.
Type:
Grant
Filed:
July 25, 2019
Date of Patent:
April 16, 2024
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Chang Sik Lee, Jung Taek Oh, Hokeun Yun, Hyeseung Song, Hyunjin Michael Kim
Abstract: The present invention relates to a pharmaceutical or food composition comprising Cinnamomum cassia pretreated extract exhibiting an excellently enhanced pharmacological effect than Cinnamomum cassia extract prepared by a conventional common extraction method of Cinnamomum cassia and extract prepared with Cinnamomum cassia single herb medicine, or a method for preventing, improving or treating gastritis or peptic ulcer using the composition. In addition, the present invention relates to a preparation method of Cinnamomum cassia pretreated extract which is characterized by pretreating Cinnamomum cassia with a non-polar solvent and extracting it with a polar solvent.
Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.
Abstract: The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
November 14, 2023
Assignee:
CHONG KUN DANG PHARMACEUTICAL CORP.
Inventors:
Jong Seo Choi, Min Soo Kim, Shin Jung Park, Jong Lae Lim
Abstract: The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.
Type:
Grant
Filed:
January 28, 2019
Date of Patent:
September 19, 2023
Assignee:
CHONG KUN DANG PHARMACEUTICAL CORP.
Inventors:
Jong Seo Choi, Min Soo Kim, Shin Jung Park, Jong Lae Lim
Abstract: The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation, wherein a first mixed part comprising esomeprazole comprises 40% by weight or less of sodium bicarbonate based on the total weight of sodium bicarbonate comprised in the preparation, and thus sodium bicarbonate is first dissolved so as to raise pH, and then esomeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.
Type:
Application
Filed:
February 18, 2021
Publication date:
March 16, 2023
Applicant:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jong Seo Choi, Min Soo Kim, Shin Jung Park
Abstract: The present invention relates to a stable pharmaceutical composition comprising an omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition having improved stability, which includes a low content of sodium bicarbonate and has excellent dissolution rate and bioavailability and a reduced side effect due to a high content of sodium bicarbonate.
Type:
Application
Filed:
July 14, 2020
Publication date:
September 15, 2022
Applicant:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jong Seo Choi, Min Soo Kim, Shin Jung Park, Jong Lae Lim
Abstract: The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
August 23, 2022
Assignee:
CHONG KUN DANG PHARMACEUTICAL CORP.
Inventors:
Changsik Lee, Jaekwang Lee, Hyeseung Song, Daekwon Bae, Nina Ha, Hyang Kim, II
Abstract: Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
May 3, 2022
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Ho Young Hwang, Ji Hye Hwang, Young Nam Lee, Sang Myoung Noh, Min Hyo Ki
Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.
Abstract: The present disclosure provides a composition for preventing or treating cancer comprising (S)—N-(4-(3-(1H-1,2,4-triazole-1-yl)-4-(3,4,5-trimethoxy-benzoyl)phenyl)thiazole-2-yl)-2-amino-3-methylbutanamide or pharmaceutically acceptable salts thereof, and an immune checkpoint inhibitor. The composition of the present disclosure achieves an excellent cancer treatment effect.
Type:
Grant
Filed:
July 25, 2018
Date of Patent:
June 29, 2021
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Soo Jin Kim, U Ji Kim, Inhak Choi, Suna Im
Abstract: The present disclosure relates to naltrexone sustained release microparticle delivery systems for the treatment of diseases ameliorated by naltrexone. The injectable microparticle delivery system includes naltrexone encapsulated in biodegradable microparticles administered in a pharmaceutically acceptable vehicle.
Type:
Grant
Filed:
October 15, 2019
Date of Patent:
May 11, 2021
Assignees:
Chong Kun Dang Pharmaceutical Corp., Purdue Research Foundation
Inventors:
Gwangheum Yoon, Bong Kwan Soh, Andrew David Otte, Kinam Park
Abstract: The present invention relates to a pharmaceutical composition with enhanced stability, containing pemetrexed or a salt thereof, and a preparation method therefor. The present invention provides an injection preparation in liquid form containing pemetrexed, capable of ensuring sufficient stability during circulation and storage by selection of an optimum material and setting of an optimum concentration range in order to secure the stability of pemetrexed. The present invention can provide a pemetrexed preparation which is readily commercially prepared, can prevent microbial contamination occurring during lyophilization or reconstitution, and has enhanced convenience of administration and stability.
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
October 6, 2020
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Min Jae Joo, Hye Jin Seo, Shin Jung Park
Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
Type:
Grant
Filed:
December 27, 2013
Date of Patent:
July 28, 2020
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Sang Phil Yoon, Ki Seong Ko, Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, So Hyun Park, Sung Bum Jung, Sung Won An, Min Hyo Ki
Abstract: The present invention relates to a transgenic pig in which an immune rejection response is suppressed during xenotransplantation, wherein a gene coding for heme oxygenase-1 (HO-1) and a gene coding for tumor necrosis factor receptor 1-Fc (TNFR1-Fc) are simultaneously expressed and a gene coding for ?-1,3-galactosyltransferase (GGTA1) is knocked out; and a method for producing the same.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
July 21, 2020
Assignees:
CHONG KUN DANG PHARMACEUTICAL CORP., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Byeong Chun Lee, Curie Ahn, Geon A Kim, Su Cheong Yeom, Su Jin Kim, Bumrae Cho, Eun Mi Lee, Sang Hoon Lee, In Chang Hwang, Hye Jin Hong
Abstract: The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
July 21, 2020
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jaekwang Lee, Yuntae Kim, Chang Sik Lee, Hyeseung Song, Dal-Yong Gwak, Jaeyoung Lee, Jung Taek Oh, Chang Gon Lee, Il Hyang Kim
Abstract: The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds.
Type:
Grant
Filed:
July 27, 2016
Date of Patent:
March 10, 2020
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jaekwang Lee, Moo Sung Ko, Younghue Han, Yuntae Kim
Abstract: The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.
Type:
Grant
Filed:
July 27, 2016
Date of Patent:
January 21, 2020
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jaekwang Lee, Younghue Han, Yuntae Kim, Daekyu Choi, Jaeki Min, Miseon Bae, Hyunmo Yang, Dohoon Kim
Abstract: The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
December 3, 2019
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Yuntae Kim, Chang Sik Lee, Jung Taek Oh, Hyeseung Song, Jin Choi, Jaeyoung Lee
Abstract: The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds.
Type:
Grant
Filed:
July 27, 2016
Date of Patent:
November 5, 2019
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Jaekwang Lee, Younghue Han, Yuntae Kim, Jaeki Min, Miseon Bae, Dohoon Kim, Seokmin Jin, Jangbeen Kyung